about
Rapid and scalable plant-based production of a cholera toxin B subunit variant to aid in mass vaccination against cholera outbreaksEnvironment Control to Improve Recombinant Protein Yields in Plants Based on Agrobacterium-Mediated Transient Gene ExpressionBiomanufacturing of protective antibodies and other therapeutics in edible plant tissues for oral applicationsMolecular farming on rescue of pharma industry for next generations.Chimeric plantibody passively protects mice against aerosolized ricin challenge.Engineering, expression in transgenic plants and characterisation of E559, a rabies virus-neutralising monoclonal antibody.Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systemsStrategies for preventing mucosal cell-associated HIV transmission.Plant-based expression of a partially humanized neutralizing monoclonal IgG directed against an immunodominant epitope on the ricin toxin A subunit.Using Computational Modeling To Optimize the Design of Antibodies That Trap Viruses in MucusBroadly Neutralizing Anti-HIV Antibodies Prevent HIV Infection of Mucosal Tissue Ex VivoEfficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicidesNon-Antiretroviral Microbicides for HIV Prevention.Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model.Antibody-based concepts for multipurpose prevention technologies.Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy.Significant impact of single N-glycan residues on the biological activity of Fc-based antibody-like fragments.Development of experimental and early investigational drugs for the treatment of Ebola virus infections.Accumulation of secreted antibodies in plant cell cultures varies according to the isotype, host species and culture conditions.Enzyme replacement for GM1-gangliosidosis: Uptake, lysosomal activation, and cellular disease correction using a novel β-galactosidase:RTB lectin fusion.Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail.Pharmacokinetics and Preliminary Safety of Pod-Intravaginal Rings Delivering the Monoclonal Antibody VRC01-N for HIV Prophylaxis in a Macaque Model.Effects of plant density on recombinant hemagglutinin yields in an Agrobacterium-mediated transient gene expression system using Nicotiana benthamiana plants.High-yield production of a human monoclonal IgG by rhizosecretion in hydroponic tobacco cultures.Plant-based production of two chimeric monoclonal IgG antibodies directed against immunodominant epitopes of Vibrio cholerae lipopolysaccharide.RTB Lectin: a novel receptor-independent delivery system for lysosomal enzyme replacement therapiesHydroponic Treatment of Nicotiana benthamiana with Kifunensine Modifies the N-glycans of Recombinant Glycoprotein Antigens to Predominantly Man9 High-Mannose Type upon Transient Overexpression.
P2860
Q21090119-FC053B2F-14C5-42F7-8E9C-1B6BDCDAB5EEQ26750828-23F13E71-3C98-4F65-B29D-1E447FCE13BEQ26766215-CEA63FA1-AAA0-46EC-B31E-BF2C79C3554AQ30252148-9EADD69A-003C-49D0-AD30-641BF6ED52B9Q33601893-4253BB52-6F80-4B2F-8FCB-2E8145B3C7EDQ33816066-7B267125-71B4-4DCB-A33C-DEDF163504A0Q34637663-B9B71693-6904-4CE2-BED5-F27D525B5F5AQ35000010-C381DB11-6880-43C1-BE70-8C37FCA3020CQ35742640-F52953AC-993B-4E15-A77F-C4A402D25E8BQ36450159-474C6F02-B593-4689-A182-052FC477A3A6Q36571900-B1A1C351-CF9C-4497-A86B-071F24CF8CEDQ36785795-AE051B5E-B099-41AA-A6D0-2C07A2B5C091Q37317845-F40191E3-1FE3-41DE-9689-9BADC92309E0Q37484236-CAE043BD-E3EA-4B98-AB87-F4A98DCEFAF1Q37601003-A889B394-79C3-48AD-B355-F3BC62FFABD6Q37725351-1C145898-CE4F-4B6E-B3C8-289842E9ABD3Q38325260-70E14070-D6D7-4F2A-B6D3-F97EB8B081E7Q38524949-BA34C9FF-C32E-4331-9E23-B4B9E3A9B71BQ39039076-7084882C-858B-4FEC-954C-1AEC05E0AD61Q40108800-13CF2613-3EE4-4473-81FF-B7E5D454C88FQ40237315-7A3DB11B-41DB-4F33-97EF-A9B5E3500167Q40239519-FA6CF55E-C713-4CF9-AF0F-DF8A51905B47Q40261619-AAB3ED98-4EF5-41F1-B04E-7E0CE65BEB09Q41188176-9A0B5959-2BDC-47E6-B15F-8EE91B2D79BCQ41342001-A2AB2064-42CD-494C-8B03-69C0D1399606Q41977743-7E633817-07F1-41A2-95EB-55E48F317269Q49470037-20181D9D-8BEF-4E52-9537-E0540E8CB392
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Emerging antibody products and Nicotiana manufacturing.
@ast
Emerging antibody products and Nicotiana manufacturing.
@en
type
label
Emerging antibody products and Nicotiana manufacturing.
@ast
Emerging antibody products and Nicotiana manufacturing.
@en
prefLabel
Emerging antibody products and Nicotiana manufacturing.
@ast
Emerging antibody products and Nicotiana manufacturing.
@en
P2093
P2860
P356
P1433
P1476
Emerging antibody products and Nicotiana manufacturing.
@en
P2093
Andrew Hiatt
Kevin J Whaley
Larry Zeitlin
P2860
P304
P356
10.4161/HV.7.3.14266
P577
2011-03-01T00:00:00Z